Pulmonary Arterial Hypertension (PAH), a rare and incurable pulmonary vascular disease. This multidisciplinary program in therapeutic innovation between three academic laboratories made it possible to: (i) identify a novel therapeutic target for the treatment of PAH, (ii) design/develop as well as validate in vivo a disruptive drug candidate with anti-remodeling properties for the curative treatment of PAH.